Skip Navigation

A Phase III, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05002569

Study #:
STUDY00148542

Start Date:
Oct 12, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05002569

View Complete Trial Details & Eligibility at ClinicalTrials.gov